论文部分内容阅读
用分子克隆与表达技术于酵母菌内合成含363个氨基酸的丙型肝炎病毒(HCV)的多肽(c100-3),以此重组的HCV 抗原建立了IgG 抗-HCV 检测方法。但是,IgG 抗-HCV 于急性HCV 感染后可迟至1年方出现,它的存在亦不意味HCV 复制,而且其滴度与病程无关,不能作为预后的标志。在病毒性感染中,IgM 型抗体常先于IgG 出现,且其滴度可反映病毒复制状态。本文作者建立了IgM 抗-HCV 的检测方法,并对急、慢性丙型肝炎患者的系列血清标
The 363-amino-acid hepatitis C virus (HCV) polypeptide (c100-3) was synthesized in yeast by molecular cloning and expression technology. The IgG anti-HCV detection method was established with this recombinant HCV antigen. However, IgG anti-HCV can appear as late as 1 year after acute HCV infection, its presence does not mean HCV replication, and its titer has nothing to do with the course of the disease, and can not be used as a marker of prognosis. In viral infections, IgM antibodies often precede IgG, and their titers reflect the viral replication status. The author of this article has established the IgM anti-HCV detection method, and the acute and chronic hepatitis C patients serum markers